Observational study of patients with liver cancer
A Longitudinal Observational Study of the Natural History and Management of Patients With Hepatocellular Carcinoma
This study is tracking patients with liver cancer to see how well different treatments work and to learn more about the disease over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Target PharmaSolutions, Inc. Industry-sponsored |
| Locations | 72 sites (Phoenix, Arizona and 71 other locations) |
| Trial ID | NCT02954094 on ClinicalTrials.gov |
What this trial studies
TARGET-HCC is a longitudinal observational study that aims to create a research registry of patients diagnosed with hepatocellular carcinoma (HCC) in both academic and community settings. The study will assess the safety and effectiveness of various therapies currently used and those that may be developed in the future. By following patients over time, the study seeks to understand the natural history of HCC and the management practices employed in real-world clinical settings.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with a confirmed diagnosis of HCC, including those eligible for various treatment options or those under observation without specific therapy.
Not a fit: Patients who are unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the management of HCC, potentially leading to improved treatment strategies and patient outcomes.
How similar studies have performed: Other observational studies in oncology have shown success in understanding disease management and improving patient outcomes, suggesting that this approach could be beneficial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Male or female patients, age ≥18 years 2. Patients with a histological/cytological or radiological diagnosis of HCC (mixed HCC cholangiocarcinoma may be included; patients who are candidates for surgical and non-surgical treatment, as well as those being followed without specific HCC therapy may be included) Exclusion Criteria: 1. Inability to provide written informed consent
Where this trial is running
Phoenix, Arizona and 71 other locations
- Banner University Medical Center — Phoenix, Arizona, United States (Terminated)
- University of Arkansas — Little Rock, Arkansas, United States (Terminated)
- University of Southern California/Norris Comprehensive Cancer Center — Los Angeles, California, United States (Terminated)
- Stanford University — Palo Alto, California, United States (Terminated)
- California Liver Research Institute — Pasadena, California, United States (Active_not_recruiting)
- University of California-Davis — Sacramento, California, United States (Terminated)
- University of California — San Francisco, California, United States (Terminated)
- Georgetown University — Washington, District of Columbia, United States (Terminated)
- Gastro Florida — Clearwater, Florida, United States (Terminated)
- University of Florida Hepatology Research at CTRB — Gainesville, Florida, United States (Active_not_recruiting)
- University of Florida Health Gastroenterology — Jacksonville, Florida, United States (Terminated)
- Schiff Center for Liver Diseases/University of Miami — Miami, Florida, United States (Active_not_recruiting)
- Tampa General Medical Group — Tampa, Florida, United States (Terminated)
- Piedmont Atlanta Hospital — Atlanta, Georgia, United States (Terminated)
- Piedmont Cancer Institute — Atlanta, Georgia, United States (Terminated)
- Emory University Hospital — Atlanta, Georgia, United States (Terminated)
- Northwestern University Division of Gastroenterology and Hepatology — Chicago, Illinois, United States (Terminated)
- Rush University Medical Center — Chicago, Illinois, United States (Terminated)
- University of Chicago — Chicago, Illinois, United States (Active_not_recruiting)
- University of Iowa Hospitals and Clinics — Iowa City, Iowa, United States (Terminated)
- Tulane University — New Orleans, Louisiana, United States (Terminated)
- Mercy Medical Center, GI Research — Baltimore, Maryland, United States (Terminated)
- Johns Hopkins University — Baltimore, Maryland, United States (Terminated)
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States (Terminated)
- University of Michigan — Ann Arbor, Michigan, United States (Terminated)
- Henry Ford Health System — Detroit, Michigan, United States (Active_not_recruiting)
- Mayo Clinic — Rochester, Minnesota, United States (Terminated)
- Southern Therapy and Advanced Research (STAR) LLC — Jackson, Mississippi, United States (Terminated)
- Saint Louis University — Saint Louis, Missouri, United States (Active_not_recruiting)
- University of Nebraska Medical Center — Omaha, Nebraska, United States (Terminated)
- Rutgers-Robert Wood Johnson Medical School — New Brunswick, New Jersey, United States (Terminated)
- Northwell Health - Center for Liver Diseases — Manhasset, New York, United States (Terminated)
- NYU Langone Health — New York, New York, United States (Active_not_recruiting)
- Weill Cornell Medical College — New York, New York, United States (Terminated)
- Columbia University — New York, New York, United States (Terminated)
- University of North Carolina at Chapel Hill — Chapel Hill, North Carolina, United States (Terminated)
- Center for Liver Disease and Transplant at CMC — Charlotte, North Carolina, United States (Terminated)
- Providence Health & Services Cancer Clinical Trials — Portland, Oregon, United States (Terminated)
- Penn State Hershey Medical Center — Hershey, Pennsylvania, United States (Terminated)
- University of Pennsylvania — Philadelphia, Pennsylvania, United States (Terminated)
- Medical University of South Carolina — Charleston, South Carolina, United States (Terminated)
- Vanderbilt University Medical Center - GI Research Office — Nashville, Tennessee, United States (Terminated)
- Clinical Research Institute@ Methodist Dallas Medical Center — Dallas, Texas, United States (Terminated)
- University of Texas Southwestern Medical Center — Dallas, Texas, United States (Active_not_recruiting)
- Baylor Scott & White All Saints — Fort Worth, Texas, United States (Terminated)
- Research Specialists of Texas — Houston, Texas, United States (Terminated)
- University of Virginia — Charlottesville, Virginia, United States (Terminated)
- Bon Secours Liver Institute of Virginia — Richmond, Virginia, United States (Active_not_recruiting)
- Virginia Commonwealth University — Richmond, Virginia, United States (Terminated)
- Harborview Medical Center — Seattle, Washington, United States (Terminated)
+22 more sites — see ClinicalTrials.gov for the full list.
Study contacts
- Study coordinator: Stephanie Harrison
- Email: sharrison@targetrwe.com
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.